Elaiapharm

Elaiapharm is a French contract development and manufacturing organization (CDMO) specializing in the production of liquid and semi-solid pharmaceutical forms. Based in the Sophia Antipolis technology park, the company provides comprehensive services including formulation development, clinical batch production, and commercial-scale manufacturing. The facility is notably equipped to handle high-potency drugs and cytotoxic products, maintaining specialized containment areas for these sensitive materials. Their product portfolio includes syrups, oral drops, nasal sprays, ointments, and gels packaged in various formats. Since its acquisition by the Fareva Group in 2009, Elaiapharm has integrated into one of the world's leading subcontracting networks for the pharmaceutical industry. The site operates under global regulatory standards, including GMP certifications, to serve an international pharmaceutical clientele.